Is Adeshwar Meditex overvalued or undervalued?

As of 1 October 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when compared to its peers in the healthcare services sector. Key ratios include a PE ratio of 11.29, an EV to EBITDA of 7.56, and a Price to Book Value of 0.63, which suggest a favorable valuation relative to its earnings and asset base.
In comparison to peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 55.34, and Blue Jet Health at 32.02. Additionally, the EV to EBITDA ratio of 7.56 is more attractive than that of Poly Medicure's 41.19, indicating that Adeshwar Meditex is priced more favorably in terms of its operational earnings. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -37.69% against the Sensex's 3.64%, the current valuation metrics suggest that the stock is positioned for potential upside.